The registration for the biologic dupilumab (Dupixent) has been extended from adults and adolescents with severe, uncontrolled atopic dermatitis to include the treatment of children aged six to eleven years. The expanded TGA indication allows private prescription of dupilumab for children who have failed to respond to optimally prescribed topical treatments for severe, uncontrolled atopic ...
Dupilumab indication extended to children with severe eczema
By Michael Woodhead
1 Sep 2021